Laura Remacha

Laura Remacha

Auto-generated profile, based on publicly available information

Laura Remacha

Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
LRLaura Remacha
Laura Remacha
MCMaria Currás-Freixes
Maria Currás-Freixes
RTRaul Torres-Ruiz
Raul Torres-Ruiz
FSFrancesca Schiavi
Francesca Schiavi
RTRafael Torres-Perez
Rafael Torres-Perez
Alberto CasconAlberto Cascon
Alberto Cascon

12 October 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LRLaura Remacha
Laura Remacha
ICIñaki Comino-Mendez
Iñaki Comino-Mendez
SRSusan Richter
Susan Richter
LCLaura Contreras
Laura Contreras
MCMaría Currás-Freixes
María Currás-Freixes
Alberto CasconAlberto Cascon
Alberto Cascon
Purpose: Mutations in Krebs cycle genes are frequently found in patients with pheochromocytomas/paragangliomas. Disruption of SDH, FH or MDH2 enzymatic activities lead to accumulation of specific metabolites, which give rise to epigenetic changes in the genome that cause a characteristic hypermethylated phenotype. Tumors showing this phenotype, but no alterations in the known predisposing genes, could harbor mutations in other Krebs cycle genes. Experimental Design: We used downregulation and methylation of RBP1, as a marker of a hypermethylation phenotype, to select eleven pheochromocytomas and paragangliomas for targeted exome sequencing of a panel of Krebs cycle-related genes. Methylation profiling, metabolite assessment and additional analyses were also performed in selected cases. Results: One of the 11 tumors was found to carry a known cancer-predisposing somatic mutation in IDH1. A variant in GOT2, c.357A>T, found in a patient with multiple tumors, was associated with higher tumor mRNA and protein expression levels, increased GOT2 enzymatic activity in lymphoblastic cells, and altered metabolite ratios both in tumors and in GOT2 knockdown HeLa cells transfected with the variant. Array methylation-based analysis uncovered a somatic epigenetic mutation in SDHC in a patient with multiple pheochromocytomas and a gastrointestinal stromal tumor. Finally, a truncating germline IDH3B mutation was found in a patient with a single paraganglioma showing an altered α-ketoglutarate/isocitrate ratio. Conclusions: This study further attests to the relevance of the Krebs cycle in the development of PCC and PGL, and points to a potential role of other metabolic enzymes involved in metabolite exchange between mitochondria and cytosol. Clin Cancer Res; 23(20); 6315–24. ©2017 AACR.

1 July 2017 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
MCMaria Currás-Freixes
Maria Currás-Freixes
EPElena Piñeiro-Yáñez
Elena Piñeiro-Yáñez
CMCristina Montero-Conde
Cristina Montero-Conde
MAMaria Apellaniz-Ruiz
Maria Apellaniz-Ruiz
BCBruna Calsina
Bruna Calsina
MRMercedes Robledo
Mercedes Robledo

1 June 2016 in Cancer Genetics
Verified
Journal Article
Closed access
ICIñaki Comino-Mendez
Iñaki Comino-Mendez
ÁTÁgueda M. Tejera
Águeda M. Tejera
MCMaría Currás-Freixes
María Currás-Freixes
LRLaura Remacha
Laura Remacha
PGPablo Gonzalvo
Pablo Gonzalvo
Alberto CasconAlberto Cascon
Alberto Cascon

16 May 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Alberto CasconAlberto Cascon
Alberto Cascon
LRLaura Remacha
Laura Remacha
BCBruna Calsina
Bruna Calsina
MRMercedes Robledo
Mercedes Robledo
Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors that show the highest heritability of all human neoplasms and represent a paradoxical example of genetic heterogeneity. Amongst the elevated number of genes involved in the hereditary predisposition to the disease (at least nineteen) there are eleven tricarboxylic acid (TCA) cycle-related genes, some of which are also involved in the development of congenital recessive neurological disorders and other cancers such as cutaneous and uterine leiomyomas, gastrointestinal tumors and renal cancer. Somatic or germline mutation of genes encoding enzymes catalyzing pivotal steps of the TCA cycle not only disrupts cellular respiration, but also causes severe alterations in mitochondrial metabolite pools. These latter alterations lead to aberrant accumulation of “oncometabolites” that, in the end, may lead to deregulation of the metabolic adaptation of cells to hypoxia, inhibition of the DNA repair processes and overall pathological changes in gene expression. In this review, we will address the TCA cycle mutations leading to the development of PPGL, and we will discuss the relevance of these mutations for the transformation of neural crest-derived cells and potential therapeutic approaches based on the emerging knowledge of underlying molecular alterations.